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ABSTRACT
Residual renal function and the integrity of the peritoneal membrane contribute to morbidity and
mortality among patients treated with peritoneal dialysis. Glucose and its degradation products
likely contribute to the deterioration of the remnant kidney and damage to the peritoneum.
Benfotiamine decreases glucose-induced tissue damage, suggesting the potential for benefit in
peritoneal dialysis. Here, in a model of peritoneal dialysis in uremic rats, treatment with benfo-
tiamine decreased peritoneal fibrosis, markers of inflammation, and neovascularization, resulting in
improved characteristics of peritoneal transport. Furthermore, rats treated with benfotiamine ex-
hibited lower expression of advanced glycation endproducts and their receptor in the peritoneum
and the kidney, reduced glomerular and tubulointerstitial damage, and less albuminuria. Increased
activity of transketolase in tissue and blood contributed to the protective effects of benfotiamine.
In primary human peritoneal mesothelial cells, the addition of benfotiamine led to enhanced
transketolase activity and decreased expression of advanced glycation endproducts and their
receptor. Taken together, these data suggest that benfotiamine protects the peritoneal membrane
and remnant kidney in a rat model of peritoneal dialysis and uremia.
J Am Soc Nephrol 22: 914–926, 2011. doi: 10.1681/ASN.2010070750
Peritoneal dialysis (PD) is a well accepted alterna-
tive to hemodialysis in the treatment of end-stage
renal disease. Long-term PD is limited because of
structural and functional changes of the peritoneal
membrane because of a loss of ultrafiltration, in-
duced by PD fluids (PDF) containing high glucose
concentrations and glucose degradation products
(GDP).1 Glucose and GDP have not only been
shown to be the culprit of peritoneal damage but are
also suspected to be causally involved in remnant
kidney damage. This is of particular importance be-
cause residual renal function (RRF) is highly asso-
ciated with mortality and morbidity in PD pa-
tients.2 A recent animal experiment demonstrated
that renal toxicity is mediated by GDP.3 This has
been confirmed by two prospective randomized
clinical studies—the Balnet trial and recently the
DIUREST study—demonstrating a better preser-
vation of RRF in PD patients using low-GDP
PDF.4,5 Until today therapeutic options preventing
glucose and GDP-induced toxicity are certainly
needed. Hitherto, although promising, experimen-
tal trials did not find their way into clinical practice.
Benfotiamine (BF; S-benzoyl-thiaminemono-
Received July 20, 2010. Accepted January 16, 2011.
Published online ahead of print. Publication date available at
www.jasn.org.
L.P.K. and S.M.K. contributed equally to this work.
Correspondence: Lars P. Kihm, Department of Nephrology, Uni-
versity of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidel-
berg, Germany. Phone: 49622191120; Fax: 4962219112990;
E-mail: lars.kihm@med.uni-heidelberg.de
Copyright © 2011 by the American Society of Nephrology
BASIC RESEARCH www.jasn.org
914 ISSN : 1046-6673/2205-914 J Am Soc Nephrol 22: 914–926, 2011
phosphate) prevented high-glucose-induced tissue damage by
an activation of the enzyme transketolase (TK)6 and pleiotro-
pic direct antioxidative effects in diabetes.7 Until now there are
no data available concerning BF in PD or in uremia.
The purpose of our experimental study was to address
whether treatment with BF prevents local peritoneal and sys-
temic kidney damage in an animal model of PD therapy.
RESULTS
Animals
Animal Characteristics.
Sprague-Dawley rats receiving peritoneal injections revealed a
significantly lower body weight compared with rats without
peritoneal injections. The serum creatinine and urea of SNX
(SNX) rats were significantly higher than the levels of the
Sham-operated animals. BP was significantly higher in SNX
rats, and hemoglobin values were significantly decreased in
SNX rats (Table 1).
TK Activity, Reactive Oxygen Species, and Protein Fluorescence
in Serum and Urine.
The diversion of metabolites toward the pentose-phosphate
pathway via the enzyme TK is dependent on its cofactor BF.6
Blood, peritoneal, and renal TK activity of SNX rats treated
with BF was significantly higher compared with the untreated
SNX rats (Figure 1, A andB).Glucose anduremia are known to
induce the generation of reactive oxygen species (ROS) and
protein fluorescence.8,9 SNX rats had higher levels of serum
ROS and serum protein fluorescence compared with Sham
rats. SNXBF rats demonstrated lower serumROS and serum
protein fluorescence compared with SNX rats without BF sub-
stitution. Compared with Sham and SNX animals treated with
BF, SNX rats revealed significantly lower urinary protein fluo-
rescence (Figure 1, C and D).
GDP and Advanced Glycation Endproducts and Their Receptor
in the Peritoneum.
Peritoneal biopsies of PD patients revealed an enhanced ex-
pression of advanced glycation endproducts (AGE) in the peri-
tonealmembrane and a consecutive upregulation of the recep-
tor for AGE (RAGE) during long-term PD treatment.10 In the
study presented here, SNX rats treatedwith BF revealed a lower
peritoneal content of methylglyoxal-derived AGE (MG-AGE),
N-carboxymethyllysine (CML), and RAGE compared with
SNX rats not treated with BF. SNX rats receiving PDF instilla-
tion had the highest expression ofMG-AGE, CML, and RAGE.
SNX rats receiving PDF instillation and BF treatment revealed
significantly lower MG-AGE, CML, and RAGE expression
(Figure 2, A through C).
Peritoneal Fibrosis and Epithelial-to-Mesenchymal Transition.
Ongoing PD and uremia per se result in progressive fibrosis
and thickening of the peritoneal membrane1 that is medi-
ated by TGF (TGF1).10,11 Additionally an epithelial-to-
mesenchymal transition (EMT) of human peritoneal meso-
thelial cells (HPMC) that is indicated by -smooth muscle
actin (SMA) is discussed.12 Peritoneal thickness, staining
for TGF1, and SMA were significantly increased in SNX
rats compared with Sham rats. SNX animals treated with BF
revealed significantly decreased peritoneal thickness and
lower TGF1 and SMA expression compared with SNX
rats without BF. SNX rats with PD treatment revealed the
highest expression of SMA and TGF1 and the highest
increase in the thickening of the peritoneal membrane. PD-
and BF-treated SNX rats showed significantly decreased
thickening of the peritoneal membrane and staining for
TGF1 and SMA compared with PD-treated SNX rats not
receiving BF (Figure 3, A through D).
Peritoneal Neovascularization.
A contributing factor leading to insufficient ultrafiltration of
the peritoneal membrane is an increasing number of vessels
mediated by vascular endothelial growth factor (VEGF), as
shown by De Vriese and co-workers.13 SNX rats demonstrated
significantly more vessels per area and significantly increased
staining for VEGF compared with control rats. The most pro-
nounced staining for VEGFwas observed in PD-treated rats. A
substitution of BF was associated with significantly fewer ves-
sels per area and decreased staining for VEGF (Figure 4, A and
B, Supplementary Figure 1).
Peritoneal Inflammation.
To elucidate the inflammatory status of the peritoneal
membrane, CD3-positive leukocytes were counted and the
expression of IL-6 was analyzed. SNX rats showed signifi-
cantly elevated peritoneal staining for IL-6 and a higher
Table 1. Animal characteristics
Characteristic
Sham
(n  12)
SNX
(n  12)
SNXBF
(n  12)
SNX IP
(n  12)
SNXPD
(n  12)
SNXPDBF
(n  12)
Body weight (g) 526  13.5 489  17.9 483  18.7 447  16.8 441  9.16 454  5.63
Hemoglobin (g/dl) 12.9  0.67 8.38  0.70b 8.67  1.06b 8.30  1.53 8.63  0.79 8.64  1.39
Serum creatinine (mg/dl) 0.24  0.02 0.70  0.10a 0.66  0.05a 0.74  0.03 0.73  0.06 0.67  0.06
Serum urea (mg/dl) 41.3  3.50 90.1  11.2a 85.6  9.74a 87.6  13.0 85.6  7.53 84.2  10.7
BP (mmHg) 69.6  5.57 85.5  6.64c 83.6  3.48c 86.6  5.08 84.9  4.23 85.3  4.82
IP, intraperitoneal.
aP  0.001 versus Sham; bP  0.01 versus Sham; cP  0.05 versus Sham.
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amount of CD3-positive cells compared with Sham-operated
rats, whereas BF substitution in SNX rats was associated with a
significantly reduced staining for IL-6 and CD3-positive cells.
SNX rats treated with PD showed the highest expression of
IL-6. IL-6 staining was significantly decreased in PD-treated
rats when BF was substituted (Figure 4, C and D).
Peritoneal Equilibration Test.
The quality of PD treatment depends on
adequate ultrafiltration. An appropriate
method to determine the ultrafiltration
capacity of the patient’s peritoneal mem-
brane is the peritoneal equilibration
test.14 The quotient of dialysate and
plasma concentration (D/P) of toxic ure-
mic substances allows for determining
the transport status of a peritoneal mem-
brane. During the course of PD treat-
ment, most patients convert to a faster
transport type with a loss of ultrafiltra-
tion capacity because of changes of the
peritoneal membrane as described
above.15 D/P creatinine showed no sig-
nificant differences, whereas D/P urea
was highest in the SNX rats treated with
PDF, demonstrating a faster transport
type compared with SNX rats with con-
trol injection. SNX rats undergoing PDF
instillation treated with BF showed a sig-
nificantly slower transport type (Figure 5A).
D/P sodium as a marker for aquaporin
function of the peritoneal membrane did
not significantly differ between the groups
(data not shown).
Albuminuria.
Albuminuria was assessed as an appro-
priate functional marker of kidney dam-
age. SNX rats developed significantly in-
creased albuminuria compared with
Sham rats. Albuminuria was significantly
decreased in SNX animals treated with BF
compared with SNX rats without BF. The
highest levels of albuminuria were seen in
SNX rats treated with PDF. SNX rats un-
dergoing PD and BF treatment showed
significantly less albuminuria than SNX
rats undergoing PD treatment without
BF supplementation (Figure 5B).
Histologic Findings of the Kidney.
Newer insights in the pathology of PD
treatment indicated a systemic toxicity of
PDF. Therefore, we investigated histo-
morphology of the kidneys using appro-
priate semiquantitative scores for glo-
merular and tubular kidney injury.3 SNX rats revealed a
significantly higher glomerular sclerosis index (GSI), tubu-
lointerstitial injury index (TII), and interstitial area of the
tubulointerstitium (IA) compared with Sham rats. SNX rats
treated with BF showed significantly lower GSI, TII, and IA
than untreated SNX rats. SNX animals receiving PD treat-
Figure 1. Increased TK activity, decreased serum ROS and protein fluorescence , and
increased urine proteine fluorescence in animals with BF treatment. Increased blood
TK activity was observable in uremic rats receiving BF for 12 weeks (A). Treatment with
BF resulted in a higher tissue activity of TK in the peritoneum and in the kidney (A and
B). Uremic rats developed higher levels of serum ROS compared with Sham rats. PD
treatment accentuates the generation of ROS in uremic rats (C). Serum protein fluo-
rescence as a marker for systemic protein glycation was increased in uremic animals
and was escalated when PD treatment was performed but was ameliorated when BF
was substituted, presumably because rats treated with BF excreted a higher amount of
glycated protein via the urine (D). All results represent mean  SEM of 12 animals per
group. ***P  0.001 versus Sham, *P  0.05 versus Sham, §§§P  0.001 versus SNX,
§§P  0.01 versus SNX, §P  0.05 versus SNX, $$P  0.01 versus SNX intraperitoneal,
$P  0.05 versus SNX intraperitoneal, ###P  0.001 versus SNXPD, ##P  0.01 versus
SNXPD, #P  0.05 versus SNXPD.
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ment revealed the highest GSI, TII, and IA. SNX rats treated
with PDF and BF revealed significantly lower GSI and IA
compared with PD-treated SNX rats without BF substitu-
tion (Figure 6, A through D).
AGE and RAGE in the Kidney.
Consistent with the results of the analysis of the peritoneal
membrane, SNX rats revealed significantly higher glomer-
ular and tubular CML and RAGE expression compared with
Sham-operated rats. SNX rats treated with BF revealed sig-
nificantly lower glomerular expression of CML and RAGE
compared with untreated SNX rats. Animals treated with
PD solutions revealed the highest glomerular and tubular
expression of CML and RAGE. PD- and BF-treated SNX rats
showed significantly less glomerular CML and RAGE ex-
pression than SNX rats treated with PDF but not BF
(Figure 7, A and B).
Renal Fibrosis.
To confirm the morphologic markers of
kidney injury, we performed staining for
Sirius Red (Figure 8A) and TGF1 (Fig-
ure 8B). SNX rats showed significantly
increased tubular and glomerular stain-
ing for Sirius Red (data not shown) and
TGF1 compared with Sham rats. The
glomerular expression of TGF1 was sig-
nificantly increased in SNX rats treated
with PDF compared with SNX rats with
intraperitoneal puncture alone. PD-
treated SNX rats receiving BF revealed
significantly less glomerular staining in-
tensity for TGF1 compared with the
SNX rats with PDF injection but without
BF treatment (Figure 8B).
Renal VEGF.
There is some evidence for an altered re-
nal vascularization in uremia and during
PD that is associated with an increase of
VEGF.3,16 SNX rats showed significantly
increased tubular and glomerular stain-
ing for VEGF compared with Sham rats.
The glomerular expression of VEGF was
significantly increased in SNX rats
treated with PDF compared with SNX
rats with intraperitoneal puncture alone.
PD-treated SNX rats receiving BF re-
vealed significantly less glomerular stain-
ing intensity for VEGF compared with
the SNX rats with PDF injection but
without BF treatment (Figure 9A).
Inflammatory Status of the Kidney.
In addition to renal fibrosis, SNX rats re-
vealed a higher tubular and glomerular
expression of IL-6 compared with Sham rats. Glomerular
IL-6 was significantly increased in SNX rats treated with
PDF compared with SNX rats with intraperitoneal punc-
ture. PD-treated SNX rats receiving BF revealed signifi-
cantly lower glomerular IL-6 expression compared with the
SNX rats with PDF injection but without BF treatment (Fig-
ure 9B). Tubular CD3-positive cell count was significantly
elevated in SNX rats compared with Sham rats. SNX rats
treated with BF tended to have fewer CD3-positive cells in
the kidney (Figure 9C).
Cell Culture
Cell Viability.
In HPMC treated with low- and high-glucose PDF, cytotoxic-
ity was slightly but not significantly increased compared with
control cells (control: 4.30  0.57% versus PDF1.5: 4.45 
0.91% versus PDF3.9: 6.14 1.30%, NS).
Figure 2. Decreased peritoneal expression of AGE and RAGE in rats treated with
BF. The peritoneal expression of MG-AGE and CML was highest in animals treated
with PD. BF substitution reduced the expression in uremic animals and uremic
animals with PD treatment (A and B). Representative photographs of the uremic
groups are given in panel B. RAGE was most expressed in the peritoneal membrane
of uremic rats treated with PD. A supplementation of BF abrogated the upregula-
tion of RAGE in the peritoneum during long-term PD (C). All results represent
mean  SEM of 12 animals per group; light microscopy of CML magnification 
400. ***P  0.001 versus Sham, *P  0.05 versus Sham, §§P  0.01 versus SNX,
§P  0.05 versus SNX, $$$P  0.001 versus SNX intraperitoneal, $$P  0.01 versus
SNX intraperitoneal, $P  0.05 versus SNX intraperitoneal, ##P  0.01 versus
SNXPD, #P  0.05 versus SNXPD.
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TK.
To analyze the expression of TK in cultured primary HPMC, we
incubated cellswith low- andhigh-glucose PDFwith andwithout
BF. In line with the animal experiments, TK expression was sig-
nificantly higher in the controlBF and PDF1.5BF group in
comparison to the respective groups without BF. In the high-
glucose group, nodifferencewas observablewhen incubatedwith
or without BF (Supplementary Figure 3A).
Marker of Oxidative Stress.
Next, the expression of the oxidative stress marker endothelial
nitricoxide synthase (eNOS)wasdetermined.WhenHPMCwere
incubatedwith low- andhigh-glucose-containingPDF, eNOSex-
pression increased, whereas the addition of BF resulted in lower
eNOS (Supplementary Figure 3B).
RAGE.
We then examined the effect of BF on RAGE regulation. In
accordance with the animal experiments, a significant reduc-
tion of RAGE could be found in the PDF
groups when incubated with BF (Supple-
mentary Figure 3C).
Marker of Inflammation.
To determine inflammation, ELISA of
HPMC supernatant was carried out. IL-6
release was at least partially reduced after
treatment with high-glucose-containing
PDF after incubationwith BF (Supplemen-
tary Figure 3D).
DISCUSSION
We could demonstrate protective local and
systemic effects of BF in an animalmodel of
PD and in cultured primaryHPMC. In PD,
high glucose and GDP are the main con-
tributors for peritoneal and systemic dam-
age caused by PDF; hence, preventive strat-
egies are of particular interest. BF has been
shown to prevent diabetic complications in
vivo and in vitro. We examined an animal
model and cell culture study simulating
PD-related peritoneal damage induced by
uremia and PDF exposure. The expression
of markers indicating peritoneal fibrosis,
neovascularization, and inflammation were
markedly elevated in SNX rats compared
with Sham rats; this was even more accentu-
ated when PDwas performed. These protec-
tive properties of BF could be confirmed in
our HPMC culture experiments.
The salient finding of the study is that
BF substitution is not only able to reduce
peritoneal AGE accumulation, fibrosis, neovascularization,
and inflammation in uremic rats with and without PD treat-
ment, but it also preserves the remnant kidney.
Our model combining uremia and PD exposure, inducing
peritonealmembrane damage with consecutive impairment of
the peritoneal function, is applicable for studying the patho-
genesis of peritoneal damage as it mimics uremic patients on
long-term PD. An indwelling PD catheter and a PD model
based on daily injections cause alterations of the peritoneal
membrane.17 It seems that a model utilizing injections twice
daily might lead to less artificial alteration and inflammatory
response of the peritoneal membrane.17,18 Hence, different
mechanisms underlying peritoneal damage are operative in
our model combining uremia and PD. There is growing evi-
dence for an alteration of the peritoneal membrane due to
uremia per se. This has been shown in human peritoneal biop-
sies by Williams et al.1 and was later on confirmed by Honda
and colleagues.19 Our data are in line with previous studies of
uremic rats, revealing uremia-induced increased thickening,
Figure 3. Reduced peritoneal thickening, fibrosis and EMT in rats with BF treatment. In
comparison to Sham rats, uremic rats demonstrated a thickening of the peritoneal mem-
brane that is most enhanced when PD treatment was performed. A substitution of BF
reduced the thickening of the membrane (A), apparent in the representative photographs
of the peritoneal Sirius Red staining (B). As a marker of ongoing fibrosis, TGF1 was
evaluated and displayed similar results—an enhancement because of uremia and a reduc-
tion when BF was given (C). Similar results were obtainable for the staining for SMA as a
marker for EMT (D). All results represent mean  SEM of 12 animals per group; light
microscopy of Sirius Red magnification  400. ***P  0.001 versus Sham, **P  0.01
versus Sham, §§§P  0.001 versus SNX, §P  0.05 versus SNX, $$$P  0.001 versus SNX
intraperitoneal, $$P 0.01 versus SNX intraperitoneal, ###P 0.001 versus SNXPD, #P
0.05 versus SNXPD.
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accentuated fibrosis, and functional changes of the peritoneal
membrane.11,20,21
However, glucose-induced damage mechanisms play a piv-
otal role in PD. BF has been shown to reduce diabetes-induced
tissue damage in vivo and in vitro.6,22–29 Until now there have
been no data available dealing with uremia or PD.We chose to
use BF rather than thiamine for these studies because it has a
higher bioavailability than thiamine.30
BF is thought to act through at least five different mecha-
nisms. Activation of the hexosamine pathway with subsequent
decrease in the accumulation of deleterious glucose metabo-
lites seems to be involved. Normalization of protein kinase C
activity along with prevention of nuclear factor-B activation
has been found in retinas. A reduced accumulation of AGE has
been postulated.6 Correction of imbalances in the polyol path-
way by decreasing aldose reductase activity25 and direct anti-
oxidant properties of BF have been reported.7 We chose to use
high-glucose-containing biocompatible PDF with a low
amount of GDP concerning the mechanis-
tic understanding of BF as an activator of
the pentose phosphate pathway enzyme
TK.6 Consecutively, a high-glucose driven
formation of AGE is thought to be de-
creased by TK, but an effect of BF on pre-
formed GDP is doubtful.
As a crucial pathway leading to perito-
neal damage by pronounced neovascular-
ization, fibrosis, and inflammation, the
role of AGE31 and the interaction with its
receptor RAGE have been identified.9 Our
study confirms the important role of the
AGE-RAGE interaction and demonstrates
a significant reduction of AGE accumula-
tion and downregulation of RAGE because
of BF substitution. These animal findings
have been confirmed by our cell culture ex-
periments with primary HPMC. We chose
primary HPMC rather than a cell line to
resemble the in vivo situation. Our results
are in line with a previously reported in-
creased accumulation of AGE in the hu-
man peritoneal membrane during PD
treatment and an upregulation of RAGE.10
Treatment with BF produced a downregu-
lation of RAGE, presumably because of a
lack of ligands, as our analysis of ROS and
AGE-specific fluorescence suggests.
The potential pleiotropic antioxidative ef-
fects of BF seem to be reasonable particularly
for an altered neovascularization because it
was reported that not only the AGE-RAGE
interaction31 but especially increased oxida-
tive stress leads toapronouncedneovascular-
ization during PD treatment.32 Our study
supports the antioxidative and antiangioge-
netic effects of BF through a decreased peritoneal number of ves-
sels per area and a reduced staining for VEGF, presumably the
culprit initiatorofperitonealneovascularization.13Within the set-
ting that uremia is associated with increased oxidative stress,8 it is
of special interest that uremic rats treated with BF revealed de-
creased kidney damage.
Apart from these antioxidative properties, what might be
other possible explanations for the preventive effects of BF in
the uremic milieu? It has been known for decades that uremic
patients present a reduced TK activity33–35 as a consequence of
lowered vitamin B1 levels.30 This phenomenon is pronounced
in PD patients, whereas TK activity is gradable by application
of thiamin not only in the PD patient, but possibly also in the
renal failure patient.36,37
In addition to the decreased morphologic signs of perito-
neal damage, the salient finding of the study is the protective
role of BF for the remnant kidney in a model of PD. This is of
particular relevance because large clinical studies demon-
Figure 4. Diminished peritoneal neovascularization in animals treated with BF. SNX
rats developed a significantly increased number of peritoneal vessels compared with
Sham rats. BF treatment attenuated peritoneal neovascularization that was most pro-
nounced in PD treatment (A). To confirm these results, staining for VEGF was per-
formed and resulted in similar observations (B). For determination of inflammatory
peritoneal formation, staining for IL-6 was performed and CD3-positive leukocytes
were counted. Analog results demonstrated an increase of peritoneal inflammation be-
cause of uremia that was most present in uremic animals treated with PD and was less
apparent when BF was substituted (C and D). All results represent mean  SEM of 12
animals per group. ***P  0.001 versus Sham, *P  0.05 versus Sham, §§P  0.01 versus
SNX, §P  0.05 versus SNX, $$$P  0.001 versus SNX intraperitoneal, $$P  0.01 versus
SNX intraperitoneal, $P  0.05 versus SNX intraperitoneal, #P  0.05 versus SNXPD.
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strated a higher morbidity and mortality associated with a de-
cline of RRF in PD patients.5,38 It has been demonstrated that
GDP enter the systemic circulation39 and lead to deterioration
of RRF. Recent animal models demonstrate that PD treatment
might induce kidney damage.3,40 Therefore, treatment options
focusing on the prevention of glucose and GDP-induced tox-
icity are of great interest.
One has to keep in mind that the rats used were nondiabetic
rats, so we can assume that substitution of BFmay ameliorate the
development and progression of chronic kidney damage per se.
Hitherto, BF has been shown to prevent diabetic complications.
The study presented here expands its potential indications at least
to PDpatients and possibly also to renal failure patients.Whether
BF will meet the condition as a new promising and preventive
agent has to be established in further studies.
CONCISE METHODS
Animals
Experimental Design.
Twelve-week-old male Sprague-Dawley rats (150 to 200 g; Charles
River Laboratories, Sulzfeld, Germany) were maintained in single
cages under conditions of constant temperature and humidity ac-
cording to the guidelines of the Institute of Laboratory Animal
Science of the University of Heidelberg. After 1 week of adaptation,
the rats were subjected to two-step surgical SNX or a correspond-
ing Sham operation as described before.41 In brief, rats were anes-
thetized with 0.02 ml of xylazine (Rompun 2%; Bayer Co., Le-
verkusen, Germany) and 0.2 ml of ketamine (Ketanest 10%;WDT,
Garbsen, Germany). In a first operation, the right kidney was de-
capsulated (Sham operation) with or without subsequent nephrec-
tomy. After 1 week, the cortex of the left kidney was subtotally
resected. An amount of cortex corresponding to two-thirds of the
weight of the right kidney was removed. Six groups were studied. A
first group of rats received a decapsulation of both kidneys and was
then kept unmanipulated to obtain baseline histologic and molec-
ular data (Sham). The second group was implemented to obtain
uremia-associated histologic and molecular data (SNX). The third
group received rat chow containing BF (Wo¨rwag Pharma, Bo¨blin-
gen, Germany) at a dose of 80mg per kilogram body weight per day
(SNXBF). In a fourth group, SNX rats received an intraperito-
neal injection without instilling solution as a control for puncture
trauma (SNX intraperitoneal). In the fifth and sixth groups, SNX
rats received an intraperitoneal injection of 10 ml of Gambrosol
Trio 10 containing 3.9% glucose (Gambro Corporate Research,
Hechingen, Germany) at 37°C under sterile conditions twice daily
without BF treatment (SNXPD) or with BF treatment, respec-
tively (SNXPDBF). The experiment was terminated for all rats
after 12 weeks.
Measurement of BP and Preparation of Renal and Peritoneal
Tissue.
Systolic BP was measured in the anesthetized rats before determina-
tion via an abdominal aorta catheter. Retrograde aortic perfusion was
performed as described earlier.3 For the morphologic and immuno-
histochemical investigations, the residual kidneys were divided, fixed
in paraformaldehyde (PFA; 6%, pH 7.6), embedded in paraffin, and
cut into 4-m-thick sections. Visceral peritoneal tissue samples were
fixed in 6% PFA (pH 7.6) and embedded in paraffin. Tissue sections
(4m thick) were stained with hematoxylin and eosin, periodic acid–
Schiff (PAS), and Sirius Red staining.
Immunohistochemical Staining of the Peritoneum and the Kidney.
For immunohistochemistry, tissue sections were deparaffinized,
rehydrated, and incubated in Tris-buffered saline (TBS). The fol-
lowing antibodies were used: anti-MG-AGE, anti-CML (BioLogo,
Kronshagen, Germany), anti-RAGE, anti-TGF1, anti-VEGF, an-
ti-PECAM CD31 (Santa Cruz Biotechnology, Santa Cruz, CA),
Figure 5. Slower transport type and decreased albuminuria in animals with BF treatment. In the peritoneal equilibration test, the
peritoneal transport types of the animals differed. Uremic animals provided a faster transport type compared with Sham rats. Uremic
animals with PD treatment showed the fastest transport status, whereas animals treated with PD and BF were comparable to
control-injection animals (A). To obtain chronic kidney damage, albuminuria was assessed. Uremic animals treated with BF revealed less
albuminuria than untreated uremic rats. Treatment with BF reduced albuminuria in uremic rats with PD treatment compared with SNX
rats treated with PD only (B). All results represent mean  SEM of 12 animals per group. ***P  0.001 versus Sham, **P  0.01 versus
Sham, §P  0.05 versus SNX, $P  0.05 versus SNX intraperitoneal, #P  0.05 versus SNXPD.
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anti-SMA (Sigma Aldrich, St Louis, MO), anti-IL-6 (Bio Trend,
Ko¨ln, Germany), and anti-CD3 (Dako, Carpineria, CA). The sec-
tions were incubated with the primary antibody overnight at 4°C
and thereafter stained with the secondary antibody, alkaline-
phosphatase-conjugated streptavidin, fast red, and peroxidase-
conjugated histofine simple stain, diaminobenzidine. Replace-
ment of the primary antibodies with TBS served as a negative
control.
Indices of Peritoneal Damage.
Semiquantitative analysis of MG-AGE, CML, RAGE, TGF1,
VEGF, and IL-6 was carried out using a scoring system that com-
prises a qualitative score of 0 to 3 (intensity of the staining: 0 no
staining, 1 low intensity, 2medium intensity, 3 high inten-
sity) and a quantitative score of 0 to 4 (0 normal, 1 1% to 25%
of tissue affected, 2  26% to 50% affected,
3  51% to 75% affected; 4  76% to 100%
affected). The two scores were multiplied,
with a maximum possible score of 12; 50 areas
per cross section were analyzed. The maximal
thickness of the submesothelial compact zone
was measured in sections oriented perpendic-
ular to the serosal surface. CD3-positive T
cells and vessel number (using PAS staining
and confirmed by PECAMCD31 staining) per
area on a 121-point grid (Leitz, Wetzlar, Ger-
many) were counted.
Indices of Renal Damage.
All semiquantitative analyses (morphology,
immunohistochemistry, and immunofluores-
cence) were performed in a blinded manner.
Sections (4 m) were stained with PAS, coun-
terstained with hematoxylin and eosin, and ex-
amined via light microscopy (Laborlux K; Leitz,
Wetzlar, Germany; magnification 200 to
400). GSI and TII were quantitatively evalu-
ated using el Nahas’s scoring system.42 GSI was
graded as follows: grade 0 normal, grade 1
1% to 25% of glomerular area affected, grade
2 26% to 50% affected, grade 3 51% to 75%
affected, and grade 4  76% to 100% af-
fected.43 TII (on the basis of the parameters of
basement membrane thickening, cell infiltra-
tion, tubular dilation, atrophy, or sloughing)
was also graded on a 0 to 4 scale. The number
of glomerular cells was obtained by counting
50 glomeruli per cross section, which were cut
along the equatorial plane. IA was quantitated
using the 121-point grid (Leica, Wetzlar, Ger-
many) devised by Kaneto et al.44 and Ishidoya
et al.45 Immunohistochemical analysis for
CML, RAGE, TGF1, VEGF, and IL-6 was
carried out using the scoring system that was
described above. Fifty areas per cross section
were analyzed; tubulointerstitium and glomeruli were viewed sep-
arately. For CD3, 50 tubulointerstitial areas per cross section were
analyzed and positive cells were counted.
TK Activity.
TK activity was determined by coupling the formation of glyceral-
dehyde-3-phosphate from ribose-5-phosphate and xylulose-5-
phosphate to the oxidation of NADH using triosephosphate
isomerase and glycero-3-phosphate dehydrogenase, as de-
scribed.46 In brief, 20l of tissue cytosolic extract was added to 200
l of assay mixture containing 14.8 mM ribose-5-phosphate, 253
M NADH, 185 U/ml triosephosphate isomerase, and 6.0 U/ml
GDH in 250 mM TBS, pH 7.8. The optical density was measured at
340 nm immediately and then every 10 minutes for 2 hours. The
activity was calculated from the linear decrease in the optical den-
Figure 6. Increased morphologic kidney damage in animals not receiving BF. To
obtain substantial damage of the remnant kidney in the SNX model, different estab-
lished scores describing glomerular and tubular changes were estimated using PAS
stained cross sections (A). SNX rats revealed an increased GSI (B), an elevated TII (C),
and a larger tubulointerstitial area (D) compared with Sham animals. A treatment with
BF alleviated glomerular sclerosis and tubular injury. PD treatment aggravated glo-
merular and tubular damage but was attenuated because of BF treatment (B through
D). All results represent mean SEM of 12 animals per group; light microscopy of PAS
staining magnification  400. ***P  0.001 versus Sham, *P  0.05 versus Sham,
§§P  0.01 versus SNX, §P  0.05 versus SNX, $P  0.05 versus SNX intraperitoneal,
##P  0.01 versus SNXPD, #P  0.05 versus SNXPD.
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sity from 10 and 80 minutes, converting this to micromoles of
NADH oxidized per minute using the extinction coefficient for
NADH, equivalent to micromoles of glyceraldehyde-3-phosphate
formed per minute by TK activity.
Total Protein Fluorescence in Sera and Urine.
Total protein fluorescence relating to oxidative and glycation fluores-
cence of sera and urine samples was performed using a spectrofluo-
rometer (LS 50 B; Perkin Elmer, U¨berlingen, Germany). For measur-
ing fluorescence, intensity excitation wavelength was set at 350 nm
and emission wavelength at 430 nm. Samples were diluted accord-
ingly.
Ancillary Measurements and Analysis of ROS in Sera.
Hemoglobin, urea, sodium, potassium, glucose, and creatinine were
measured with autoanalyzers (ADVIA 2400 and ADVIA 2120, Sie-
mens, Eschborn,Germany). ROSwere quantitated bymeasuring total
protein carbonyl content using the Cayman chemical protein car-
bonyl assay kit’s 2,4-dinitrophenylhydrazine re-
action with protein carbonyl (Cayman Chemi-
cal Company, Ann Arbor, MI).
Peritoneal Equilibration Test.
A modified mini-peritoneal equilibration test
was performed. In brief, 20 ml of PDF were in-
jected. After 1 hour, the intra-abdominal PDF
was aspirated and creatinine, urea, and sodium
were measured with autoanalyzers (ADVIA
2400, Siemens, Eschborn, Germany). D/P was
built, and the transport type was estimated ac-
cording to La Milia and co-workers.47
Measurement of Albumin in Urine.
Urinary albumin was quantitated using the
ELISA technique with a rat anti-albumin anti-
body (ICN Biomedicals, Eschwege, Germany)
using the peroxidase system as described by
Magnotti et al.48
Cell Culture
Cultivation and Characterization.
Primary HPMC were isolated, cultured, and
characterized as described elsewhere.49 In
brief, culture medium M199 was supple-
mented with penicillin (100 IU/ml), strepto-
mycin (0.1 mg/ml), insulin/transferrin (5 g/
ml), hydrocortisone (0.4 g/ml), and 10%
(vol/vol) FCS. Cell culture flasks were coated
with collagen I (BD Biosciences Heidelberg,
Germany), and HPMC from first to third pas-
sage were used. For characterization, isolated
cells of each omental sample stained positive
for cytokeratin 18 and vimentin and negative
for factor VIII and fibroblast-specific protein
1 (Supplementary Figure 2).
Incubation of HPMC with PDF and BF.
HPMC were serum deprived in M199 containing 0.1% FCS for 24
hours. The cells were then incubated for 48 hours with Gambrosol
Trio 10 (Gambro Corporate Research, Hechingen, Germany) and
with equal volume (1:1) of serum-deprived medium,50,51 in par-
ticular with control buffer ( control), PDF containing a low glu-
cose content of 1.5% ( PDF1.5), PDF containing a high glucose
content of 3.9% ( PDF3.9), and treated with  BF (50 M)
(Wo¨rwag Pharma, Bo¨blingen, Germany), respectively. All experi-
ments were repeated at least 3 times with omenta from different
patients.
Cell Viability.
Release of lactate dehydrogenase (LDH) after incubation with PDF
was measured in cell culture supernatants that were collected and
assayed immediately for LDH using a cytotoxicity detection kit
(Roche Applied Science, Mannheim, Germany). Measurements
Figure 7. Decreased glomerular expression of AGE and RAGE in BF treated rats. One
possible mechanism of ongoing kidney damage during PD treatment is mediated via
the interaction of AGE and RAGE. To clarify this, we performed glomerular and tubular
quantification of the expression of CML and RAGE. The tubular expression of CML and
RAGE (A and B) was increased in uremic rats in comparison to Sham animals without
any difference between the treatment groups, whereas the glomerular staining for
CML and RAGE reflected decreased expression of both when BF was substituted (A
and B). All results represent mean SEM of 12 animals per group. ***P 0.001 versus
Sham, **P  0.01 versus Sham, *P  0.05 versus Sham, §P  0.05 versus SNX, $$P 
0.01 versus SNX intraperitoneal, $P 0.05 versus SNX intraperitoneal, #P 0.05 versus
SNXPD.
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were performed in triplicates of at least three independent exper-
iments according to the manufacturer’s instructions. We carried
out a background control (providing information about the LDH
activity in the assay medium), a low control (spontaneous LDH
release), and a high control with 1% Triton X-100 (maximum
LDH release). Cytotoxicity is given in percent.
Immunofluorescence.
For immunofluorescence analysis, HPMC were grown on type I col-
lagen-coated glass coverslips (Sigma-Aldrich, St Louis, MO) either
fixed with methanol or 3% PBS-PFA and incubated with primary
antibodies, anti-cytokeratin 18 (Chemicon International, Hofheim,
Germany), anti-vimentin (Zytomed Systems, Berlin, Germany), anti-
fibroblast-specific protein 1 (Dako Cytomation, Denmark), anti-fac-
torVIII (F15), anti-RAGE (N16), anti-TK (N19) (goat polyclonal IgG,
Santa Cruz Biotechnology, Santa Cruz, CA), anti-eNOS (rabbit poly-
clonal, ABR, Golden, CO), and appropriate fluorescently labeled sec-
ondary antibodies. For nuclear staining, fixed cells were stained with
Hoechst 33342 (Invitrogen, Karlsruhe,Germany). A negative control
was performed using PBS instead of primary antibody. Images
were taken using a Nikon DS-Qi1Mc quantitative black and white
charge-coupled device camera attached to a Nikon Eclipse 80i up-
right microscope (Nikon, Du¨sseldorf, Germany). The same con-
trast and intensity settings were applied to samples stained with
identical antibodies.
ELISA.
IL-6 ELISA was performed referring to the manufacturers’ instruc-
tions (human IL-6 ELISA kit, Bioscience, Inc., San Diego, CA). In
brief, supernatants of incubated cells were taken and diluted ac-
cordingly. Measurement was carried out at 450 nm using a Multi-
scan FC ELISA reader (Thermo Scientific, Langenselbold, Ger-
many).
Statistical Analysis
All values are expressed as mean  SEM. Mann–Whitney and
Kruskal–Wallis tests were used as appropriate to test statistical signif-
icance. Significance level was set at P  0.05. Statistical analysis was
performed using PC-Statistik (version 5.0; Hoffmann, Giessen, Ger-
many) and GraphPad Prism (version 5.0; San Diego, CA).
ACKNOWLEDGMENTS
We thank Heike Ziebart and Peter Rieger (Department of Pathology,
University of Heidelberg, Heidelberg, Germany) for their excellent
Figure 8. Pronounced fibrosis in rats not receiving BF. Tubulointerstitial fibrosis is the common phenotype of every kidney disease. The SNX
model results in an ongoing tubulointerstitial fibrosis, representatively displayed in panel A (Sirius Red staining of the tubulointerstitium of the
uremic groups). As amarker of proceeding fibrosis, the glomerular and tubular expression of TGF1was evaluated (B). In comparison to Sham
animals, SNX rats showed enhanced glomerular and tubular expression of TGF1 that was alleviated when BF was given. Similar results were
obtained in the comparison of uremic rats treated with PD versus SNX rats treated with PD and BF (B). All results represent mean  SEM of
12 animals per group; light microscopy of Sirius Red magnification  400. ***P  0.001 versus Sham, *P  0.05 versus Sham, §P  0.05
versus SNX, $$P  0.01 versus SNX intraperitoneal, $P  0.05 versus SNX intraperitoneal, #P  0.05 versus SNXPD.
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 22: 914–926, 2011 Benfotiamine in Peritoneal Dialysis 923
technical assistance and Ulrike Haug and Caren Schmidt (Gambro
Research, Hechingen, Germany) for support.
DISCLOSURES
V.S. received research grants from Gambro Corporate Research (Hechin-
gen, Germany) and Wörwag Pharma (Böblingen, Germany).
REFERENCES
1. Williams JD, Craig KJ, Topley N, Von Ruhland
C, Fallon M, Newman GR, Mackenzie RK, Wil-
liams GT: Morphologic changes in the perito-
neal membrane of patients with renal disease.
J Am Soc Nephrol 13: 470–479, 2002
2. Bargman JM, Thorpe KE, Churchill DN: Rela-
tive contribution of residual renal function and
peritoneal clearance to adequacy of dialysis: A
reanalysis of the CANUSA study. J Am Soc
Nephrol 12: 2158–2162, 2001
3. Muller-Krebs S, Kihm LP, Zeier B, Gross ML,
Deppisch R, Wieslander A, Henle T, Penndorf I,
Oh J, Reiser J, Nawroth PP, Zeier M, Sch-
wenger V: Renal toxicity mediated by glucose
degradation products in a rat model of ad-
vanced renal failure. Eur J Clin Invest 38: 296–
305, 2008
4. Kim SG, Kim S, Hwang YH, Kim K, Oh JE,
Chung W, Oh KH, Kim HJ, Ahn C: Could solu-
tions low in glucose degradation products pre-
serve residual renal function in incident perito-
neal dialysis patients? A 1-year multicenter
prospective randomized controlled trial (Balnet
Study). Perit Dial Int 28[Suppl 3]: S117–S122,
2008
5. Haag-Weber M, Kramer R, Haake R, Islam MS,
Prischl F, Haug U, Nabut JL, Deppisch R: Low-
GDP fluid (Gambrosol trio) attenuates decline
of residual renal function in PD patients: A pro-
spective randomized study. Nephrol Dial
Transplant 25: 2288–2296, 2010
6. Hammes HP, Du X, Edelstein D, Taguchi T,
Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth
P, Hannak D, Neumaier M, Bergfeld R, Gi-
ardino I, Brownlee M: Benfotiamine blocks
three major pathways of hyperglycemic dam-
age and prevents experimental diabetic reti-
nopathy. Nat Med 9: 294–299, 2003
7. Schmid U, Stopper H, Heidland A, Schupp N:
Benfotiamine exhibits direct antioxidative ca-
pacity and prevents induction of DNA damage
in vitro. Diabetes Metab Res Rev 24: 371–377,
2008
8. D’Apolito M, Du X, Zong H, Catucci A, Maiuri L,
Trivisano T, Pettoello-Mantovani M, Campa-
nozzi A, Raia V, Pessin JE, Brownlee M, Gi-
ardino I: Urea-induced ROS generation causes
insulin resistance in mice with chronic renal
failure. J Clin Invest 120: 203–213
9. Schwenger V, Morath C, Salava A, Amann K,
Seregin Y, Deppisch R, Ritz E, Bierhaus A,
Nawroth PP, Zeier M: Damage to the perito-
neal membrane by glucose degradation prod-
ucts is mediated by the receptor for advanced
glycation end-products. J Am Soc Nephrol 17:
199–207, 2006
10. Kihm LP, Wibisono D, Muller-Krebs S, Pfisterer
F, Morath C, Gross ML, Morcos M, Seregin Y, Bierhaus A, Nawroth PP,
Zeier M, Schwenger V: RAGE expression in the human peritoneal
membrane. Nephrol Dial Transplant 23: 3302–3306, 2008
11. Guo H, Leung JC, Lam MF, Chan LY, Tsang AW, Lan HY, Lai KN:
Smad7 transgene attenuates peritoneal fibrosis in uremic rats
treated with peritoneal dialysis. J Am Soc Nephrol 18: 2689–2703,
2007
Figure 9. Accentuated inflammation in rats without BF treatment. There is some
evidence for a disturbed vascularization of the harmed kidney associated with upregu-
lation of VEGF. Staining for VEGF revealed an increased glomerular expression of
VEGF in SNX rats compared with control rats. BF substitution resulted in lowered
glomerular VEGF expression whereas tubular expression of VEGF was not influenced
by any treatment (A). Staining for IL-6 and CD3-positive cell count was performed as
markers of inflammation. Both showed similar results—an enhancement of glomerular
and tubular IL-6 expression accompanied by a higher number of CD3-positive cells per
area in uremic animals compared with Sham animals, with the highest occurrence in
uremic animals treated with PD. BF was able to reduce IL-6 expression and CD3-
positive leukocyte count (B and C). All results represent mean SEM of 12 animals per
group. ***P  0.001 versus Sham, **P  0.01 versus Sham, *P  0.05 versus Sham,
§P  0.05 versus SNX, $$P  0.01 versus SNX intraperitoneal, $P  0.05 versus SNX
intraperitoneal, #P  0.05 versus SNXPD.
BASIC RESEARCH www.jasn.org
924 Journal of the American Society of Nephrology J Am Soc Nephrol 22: 914–926, 2011
12. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-
Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA,
Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C,
Sanchez-Madrid F, Lopez-Cabrera M: Peritoneal dialysis and epitheli-
al-to-mesenchymal transition of mesothelial cells. N Engl J Med 348:
403–413, 2003
13. De Vriese AS, Tilton RG, Stephan CC, Lameire NH: Vascular endothe-
lial growth factor is essential for hyperglycemia-induced structural and
functional alterations of the peritoneal membrane. J Am Soc Nephrol
12: 1734–1741, 2001
14. Twardowski ZJ: Clinical value of standardized equilibration tests in
CAPD patients. Blood Purif 7: 95–108, 1989
15. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG:
Meta-analysis: Peritoneal membrane transport, mortality, and tech-
nique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591–
2598, 2006
16. Pawlak K, Pawlak D, Mysliwiec M: Impaired renal function and duration
of dialysis therapy are associated with oxidative stress and proathero-
genic cytokine levels in patients with end-stage renal disease. Clin
Biochem 40: 81–85, 2007
17. Flessner MF, Credit K, Henderson K, Vanpelt HM, Potter R, He Z,
Henegar J, Robert B: Peritoneal changes after exposure to sterile
solutions by catheter. J Am Soc Nephrol 18: 2294–2302, 2007
18. Flessner MF, Credit K, Richardson K, Potter R, Li X, He Z, Hoskins G,
Henegar J: Peritoneal inflammation after twenty-week exposure to
dialysis solution: Effect of solution versus catheter-foreign body reac-
tion. Perit Dial Int 30: 284–293
19. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T,
Hirano H: Impact of uremia, diabetes, and peritoneal dialysis itself on
the pathogenesis of peritoneal sclerosis: A quantitative study of peri-
toneal membrane morphology. Clin J Am Soc Nephrol 3: 720–728,
2008
20. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P,
Miyata T, Lameire N, Devuyst O: Chronic uremia induces permeability
changes, increased nitric oxide synthase expression, and structural
modifications in the peritoneum. J Am Soc Nephrol 12: 2146–2157,
2001
21. Vrtovsnik F, Coester AM, Lopes-Barreto D, de Waart DR, Van der Wal
AC, Struijk DG, Krediet RT, Zweers MM: Induction of chronic kidney
failure in a long-term peritoneal exposure model in the rat: Effects on
functional and structural peritoneal alterations. Perit Dial Int 30: 558–
569
22. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ:
Prevention of incipient diabetic nephropathy by high-dose thiamine
and benfotiamine. Diabetes 52: 2110–2120, 2003
23. Balakumar P, Sharma R, Singh M: Benfotiamine attenuates nicotine
and uric acid-induced vascular endothelial dysfunction in the rat.
Pharmacol Res 58: 356–363, 2008
24. Balakumar P, Chakkarwar VA, Singh M: Ameliorative effect of combi-
nation of benfotiamine and fenofibrate in diabetes-induced vascular
endothelial dysfunction and nephropathy in the rat.Mol Cell Biochem
320: 149–162, 2009
25. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M: Regulation of
intracellular glucose and polyol pathway by thiamine and benfo-
tiamine in vascular cells cultured in high glucose. J Biol Chem 281:
9307–9313, 2006
26. Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J: High-dose benfotiamine
rescues cardiomyocyte contractile dysfunction in streptozotocin-
induced diabetes mellitus. J Appl Physiol 100: 150–156, 2006
27. Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni
M, Campesi I, Invernici G, Spillmann F, Ward K, Madeddu P:
Benfotiamine accelerates the healing of ischaemic diabetic limbs in
mice through protein kinase B/Akt-mediated potentiation of angio-
genesis and inhibition of apoptosis. Diabetologia 49: 405–420,
2006
28. Pomero F, Molinar Min A, La Selva M, Allione A, Molinatti GM,
Porta M: Benfotiamine is similar to thiamine in correcting endothe-
lial cell defects induced by high glucose. Acta Diabetol 38: 135–
138, 2001
29. Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI, Vidal-
Cantu GC, Medina-Santillan R, Reyes-Garcia G, Granados-Soto V:
Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur
J Pharmacol 530: 48–53, 2006
30. Bitsch R, Wolf M, Moller J, Heuzeroth L, Gruneklee D: Bioavailability
assessment of the lipophilic benfotiamine as compared to a water-
soluble thiamin derivative. Ann Nutr Metab 35: 292–296, 1991
31. De Vriese AS, Flyvbjerg A, Mortier S, Tilton RG, Lameire NH: Inhibition
of the interaction of AGE-RAGE prevents hyperglycemia-induced fi-
brosis of the peritoneal membrane. J Am Soc Nephrol 14: 2109–2118,
2003
32. Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, Jeon JS, Ha H,
Lee HB: Oxidative stress during peritoneal dialysis: Implications in
functional and structural changes in the membrane. Kidney Int 69:
2022–2028, 2006
33. Lange K, Lonergan ET, Semar M, Sterzel RB: Transketolase inhibition
as a mechanism in uremic neuropathy. Trans Assoc Am Physicians 84:
172–181, 1971
34. Lonergan ET, Semar M, Sterzel RB, Treser G, Needle MA, Voyles L,
Lange K: Erythrocyte transketolase activity in dialyzed patients. A
reversible metabolic lesion of uremia. N Engl J Med 284: 1399–1403,
1971
35. Sterzel RB, Semar M, Lonergan ET, Lange K: Effect of hemodialysis on
the inhibition of nervous tissue transketolase and on uremic neurop-
athy. Trans Am Soc Artif Intern Organs 17: 77–79, 1971
36. Blumberg A, Hanck A, Sander G: Vitamin nutrition in patients on
continuous ambulatory peritoneal dialysis (CAPD). Clin Nephrol 20:
244–250, 1983
37. Boeschoten EW, Schrijver J, Krediet RT, Schreurs WH, Arisz L: Defi-
ciencies of vitamins in CAPD patients: The effect of supplementation.
Nephrol Dial Transplant 3: 187–193, 1988
38. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM: Randomized
controlled study of biocompatible peritoneal dialysis solutions: Effect
on residual renal function. Kidney Int 73: 200–206, 2008
39. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U,
Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation
products in PD fluids: Do they disappear from the peritoneal cavity
and enter the systemic circulation? Kidney Int 63: 298–305, 2003
40. Breborowicz A, Pawlaczyk K, Polubinska A, Gorna K, Wieslander A,
Carlsson O, Tam P, Wu G: Effect of peritoneal dialysis on renal
morphology and function. Nephrol Dial Transplant 21: 3539–3544,
2006
41. Dikow R, Kihm LP, Zeier M, Kapitza J, Tornig J, Amann K, Tiefenbacher
C, Ritz E: Increased infarct size in uremic rats: Reduced ischemia
tolerance? J Am Soc Nephrol 15: 1530–1536, 2004
42. el Nahas AM, Bassett AH, Cope GH, Le Carpentier JE: Role of growth
hormone in the development of experimental renal scarring. Kidney
Int 40: 29–34, 1991
43. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and
progressive glomerular damage in Dahl rats. Kidney Int 26: 137–143,
1984
44. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S: Enalapril
reduces collagen type IV synthesis and expansion of the interstitium in
the obstructed rat kidney. Kidney Int 45: 1637–1647, 1994
45. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin
II receptor antagonist ameliorates renal tubulointerstitial fibrosis
caused by unilateral ureteral obstruction. Kidney Int 47: 1285–
1294, 1995
46. Thornalley PJ, Jahan I, Ng R: Suppression of the accumulation of
triosephosphates and increased formation of methylglyoxal in human
red blood cells during hyperglycaemia by thiamine in vitro. J Biochem
129: 543–549, 2001
47. La Milia V, Di Filippo S, Crepaldi M, Del Vecchio L, Dell’Oro C, Andrulli
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 22: 914–926, 2011 Benfotiamine in Peritoneal Dialysis 925
S, Locatelli F: Mini-peritoneal equilibration test: A simple and fast
method to assess free water and small solute transport across the
peritoneal membrane. Kidney Int 68: 840–846, 2005
48. Magnotti RA Jr, Stephens GW, Rogers RK, Pesce AJ: Microplate
measurement of urinary albumin and creatinine. Clin Chem 35: 1371–
1375, 1989
49. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD: Isolation,
culture and characterization of human peritoneal mesothelial cells.
Kidney Int 37: 1563–1570, 1990
50. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL:
The triggering of human peritoneal mesothelial cell apoptosis and
oncosis by glucose and glycoxydation products. Nephrol Dial Trans-
plant 19: 2208–2216, 2004
51. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R,
Rippe B: In vitro biocompatibility of a heat-sterilized, low-toxic, and
less acidic fluid for peritoneal dialysis. Perit Dial Int 15: 158–164,
1995
Supplemental information for this article is available online at http://www.
jasn.org/.
BASIC RESEARCH www.jasn.org
926 Journal of the American Society of Nephrology J Am Soc Nephrol 22: 914–926, 2011
